Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study
Xiaola Xue, Juyi Wu, Zhenpeng Tan, Chunyu Tian, Qiong Li, Shujuan Zhou, Yuchao Xia, Shaojie Yang, Xuan Yang · 2026
Read Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study by Xiaola Xue, Juyi Wu, Zhenpeng Tan, Chunyu Tian, Qiong Li, Shujuan Zhou, Yuchao Xia, Shaojie Yang, Xuan Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13341521.txt.
Description
Immune checkpoint drugs appear usable in people with HIV and cancer, in a 2026 retrospective study by Xiaola Xue and colleagues. Ninety patients treated with PD-1 inhibitors between January 2022 and December 2024 were enrolled, including some with very low CD4 counts or detectable virus.
After matching, 56 patients were compared across HIV-positive and HIV-negative groups. Response and disease control rates were comparable, with the HIV-positive group at 16.2% response, and side effect profiles were tracked alongside survival. Data on this population have been scarce because trials often exclude them. Real-world evidence of this kind helps oncologists weigh treatment for a group long left out.
Catalog record
| CREATOR | Xiaola Xue, Juyi Wu, Zhenpeng Tan, Chunyu Tian, Qiong Li, Shujuan Zhou, Yuchao Xia, Shaojie Yang, Xuan Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37298 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |